Characteristics of Anti-IL-17/23 Biologics-induced Interstitial Pneumonia in Patients with Psoriasis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2021 Jan 7

PMID 33411857

Citations 2

Authors

Hanae Miyagawa

Hiromichi Hara

Jun Araya

Shunsuke Minagawa

Takanori Numata

Yoshinori Umezawa

Akihiko Asahina

Hidemi Nakagawa

Kazuyoshi Kuwano

Affiliations

Soon will be listed here.

Abstract

Objectives: Anti-IL-17/23 biologics are increasingly used to treat psoriasis. We aimed to elucidate characteristics of drug-induced interstitial pneumonia (DIIP) caused by anti-IL-17/23 biologics.

Methods: We retrospectively analyzed the clinical data of psoriasis patients treated with anti-IL-17/23 biologics. Chest CT was performed to evaluate DIIP. Serum KL-6 levels were measured before treatment (baseline) and during treatment.

Results: A total of 603 psoriasis patients were treated with anti-IL-17/23 biologics with mean follow-up of 21.1 months. Six patients developed DIIP at mean 14 months after initiation of the therapy. Older age, higher baseline KL-6 value and more frequent pre-existing IPs were associated with development of DIIP by univariate analysis. At the onset of DIIP, elevated serum KL-6 levels with concomitantly increased ground glass opacity (GGO) in Chest CT were demonstrated. DIIP was improved by only cessation of causative agents in five patients but steroid therapy was needed in one patient.

Conclusions: DIIP is a plausible complication of anti-IL-17/23 biologics. Age, baseline KL-6 level and underlying IP could be the risk factors for DIIP development. Serum KL-6 levels and chest CT are useful for not only predicting but also detecting DIIP caused by anti-IL-17/23 biologics.

Citing Articles

Drug-Induced Pulmonary Fibrosis: National Database Analysis.

Butranova O, Terekhina E, Zyryanov S, Gildeeva G, Abramova A, Kustov Y Biomedicines. 2025; 12(12.

PMID: 39767557 PMC: 11673829. DOI: 10.3390/biomedicines12122650.

Non-Infectious Pneumonitis and Acute Respiratory Distress Syndrome in a Patient on Ustekinumab Treatment: Case Report and Literature Review.

Cioffi V, Di Napoli G, Tozzi P, Martelli S, Bruno K, Longo A Life (Basel). 2024; 14(3).

PMID: 38541718 PMC: 10971856. DOI: 10.3390/life14030394.

Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management.

Al-Janabi A, Yiu Z Psoriasis (Auckl). 2022; 12:1-14.

PMID: 35024352 PMC: 8747772. DOI: 10.2147/PTT.S328575.

References

Yasmeen N, Sawyer L, Malottki K, Levin L, Apol E, Jemec G . Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year. J Dermatolog Treat. 2020; 33(1):204-218. DOI: 10.1080/09546634.2020.1743811. View

Lee S, An J, Kim D, Yoon M, Lee H . A Case of Interstitial Lung Disease and Autoimmune Thyroiditis Associated with Ustekinumab. Acta Derm Venereol. 2018; 99(3):331-332. DOI: 10.2340/00015555-3084. View

Hayashi M, Igarashi A, Okamura K, Suzuki T . Paradoxical exacerbation of latent interstitial pneumonia by secukinumab in a patient with psoriasis vulgaris. Br J Dermatol. 2018; 180(3):684-685. DOI: 10.1111/bjd.17424. View

Abe M, Tsushima K, Ikari J, Kawata N, Terada J, Tanabe N . Evaluation of the clinical characteristics of everolimus-induced lung injury and determination of associated risk factors. Respir Med. 2018; 134:6-11. DOI: 10.1016/j.rmed.2017.11.009. View

Ohnishi H, Yokoyama A, Kondo K, Hamada H, Abe M, Nishimura K . Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med. 2002; 165(3):378-81. DOI: 10.1164/ajrccm.165.3.2107134. View

Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M . New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest. 1989; 96(1):68-73. DOI: 10.1378/chest.96.1.68. View

Saeki H, Terui T, Morita A, Sano S, Imafuku S, Asahina A . Japanese guidance for use of biologics for psoriasis (the 2019 version). J Dermatol. 2020; 47(3):201-222. DOI: 10.1111/1346-8138.15196. View

Higashi Y, Tada K, Shimokawa M, Kawai K, Kanekura T . Elevation of serum KL-6 in patients with psoriasis treated with anti-tumour necrosis factor-α therapy. Clin Exp Dermatol. 2015; 41(1):88-90. DOI: 10.1111/ced.12544. View

Matsuno O . Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res. 2012; 13:39. PMC: 3426467. DOI: 10.1186/1465-9921-13-39. View

10.

Puig L . The role of IL 23 in the treatment of psoriasis. Expert Rev Clin Immunol. 2017; 13(6):525-534. DOI: 10.1080/1744666X.2017.1292137. View

11.

Kikuchi S, Umezawa Y, Hayashi M, Yanaba K, Fukuchi O, Ito T . Interstitial pneumonia in two patients with psoriasis during ustekinumab treatment. J Dermatol. 2015; 43(6):712-3. DOI: 10.1111/1346-8138.13250. View

12.

Sorger C, Simon J, Treudler R . [Drug-induced interstitial lung disease (DILD) during treatment with ustekinumab]. Hautarzt. 2019; 71(4):309-312. DOI: 10.1007/s00105-019-04519-9. View

13.

Skeoch S, Weatherley N, Swift A, Oldroyd A, Johns C, Hayton C . Drug-Induced Interstitial Lung Disease: A Systematic Review. J Clin Med. 2018; 7(10). PMC: 6209877. DOI: 10.3390/jcm7100356. View

14.

Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H . Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2007; 67(2):189-94. DOI: 10.1136/ard.2007.072967. View

15.

Martin D, Towne J, Kricorian G, Klekotka P, Gudjonsson J, Krueger J . The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2012; 133(1):17-26. PMC: 3568997. DOI: 10.1038/jid.2012.194. View

16.

Kajihara I, Yamada-Kanazawa S, Maeda-Otsuka S, Jinnin M, Akaike K, Ihn H . Secukinumab-induced interstitial pneumonia in a patient with psoriasis vulgaris. J Dermatol. 2017; 44(12):e322-e323. DOI: 10.1111/1346-8138.13986. View

17.

Brinker A, Cheng C, Chan V . Association of Noninfectious Pneumonia With Ustekinumab Use. JAMA Dermatol. 2018; 155(2):221-224. PMC: 6439534. DOI: 10.1001/jamadermatol.2018.4118. View

18.

Kawase S, Hattori N, Ishikawa N, Horimasu Y, Fujitaka K, Furonaka O . Change in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced interstitial lung disease. Respir Res. 2011; 12:97. PMC: 3160959. DOI: 10.1186/1465-9921-12-97. View

19.

Camus P, Fanton A, Bonniaud P, Camus C, Foucher P . Interstitial lung disease induced by drugs and radiation. Respiration. 2004; 71(4):301-26. DOI: 10.1159/000079633. View

20.

Gruchalla R . Drug metabolism, danger signals, and drug-induced hypersensitivity. J Allergy Clin Immunol. 2001; 108(4):475-88. DOI: 10.1067/mai.2001.118509. View